Myasthenia Gravis Lecture Flashcards
Definition and Pathophysiology of Myasthenia Gravis
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
The name is derived from Latin and Greek origins, fundamentally meaning "grave muscle weakness."
The disorder occurs at the neuron junction and specifically interferes with the transmission of Acetylcholine ().
The primary anatomic alteration involves an interference with the transmission of between the axonal terminal and the receptor sites of voluntary muscles.
Pathophysiologic mechanisms involving IgG antibodies:
- The body produces its own antibodies (specifically receptor antibodies) that block nerve impulse transmissions at the neuromuscular junction.
- These antibodies disrupt chemical transmission by blocking from the receptor sites of the muscular cell.
- Antibodies may accelerate the breakdown of .
- Antibodies can destroy the receptor sites entirely.
Secondary anatomic alterations of the lungs (associated with improperly managed ventilatory failure):
- Mucous accumulation.
- Airway obstruction.
- Alveolar consolidation.
- Atelectasis.
Etiology and Epidemiology
Prevalence and Demographics:
- In the United States, there are approximately people with myasthenia gravis for every people.
- Young women: Most common in those aged to , usually occurring under the age of .
- Older men: Most common in those aged to , usually occurring over the age of .
Provocative factors that often trigger clinical manifestations:
- Emotional upset.
- Physical stress.
- Exposure to extreme changes in temperature.
- Febrile illness.
- Pregnancy.
Clinical History and External Symptoms
The hallmark of myasthenia gravis is chronic muscle fatigue.
Key characteristics of muscle weakness:
- Weakness increases with activity.
- Weakness improves significantly after periods of rest.
Symptomatic manifestations:
- Facial muscle weakness.
- Ptosis: Drooping of one or both eyelids.
- Diplopia: Double vision.
- Dysphagia: Difficulty swallowing.
- Dysarthria: Difficulty speaking.
- Difficulty chewing.
- Unstable gait.
- Weakness in the arms, hands, fingers, legs, and neck, typically brought on by repetitive motions.
Progression of muscle involvement:
- Muscles controlling the eyes, eyelids, face, and throat are especially susceptible and are usually the first to be affected.
- Respiratory muscles of the diaphragm and chest wall can become weak, severely impairing ventilation.
- Impairment in deep breathing and coughing predisposes the patient to excessive bronchial secretions, pneumonia, and atelectasis.
Diagnostic Procedures
Clinical History and Diagnosis: Based on local weakness and decreased strength throughout the day.
Neurologic Examination.
Electromyography.
Blood Analysis: Specifically looking for receptor antibodies.
Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).
Ice Pack Test: Used for patients with ptosis. An ice pack is applied to the droopy eye for minutes; improvement in ptosis following the application is indicative of MG.
Edrophonium (Tensilon Challenge) Test: Used to both diagnose and monitor therapy. Edrophonium (Tensilon) is administered to observe its effect on muscle strength (measured via , , and ).
Differential Outcomes of Tensilon Challenge:
- Improvement: If symptoms improve, it is referred to as a Myasthenic Crisis, indicating a need for more anticholinesterase drug therapy.
- Worsening: If symptoms worsen, it is referred to as a Cholinergic Crisis, indicating that too much anticholinesterase medication has been given.
- Atropine: Administered to reverse the effects of Tensilon and relieve symptoms of a cholinergic crisis.
Physical Examination and Cardiopulmonary Manifestations
Physical Examination Findings:
- Respiratory Rate: Varies with the degree of muscle paralysis; severe cases may exhibit apnea.
- Cyanosis.
- Diminished breath sounds.
- General weakness in a "mind to ground" distribution.
Chest Assessment Findings:
- Diminished breath sounds.
- Crackles and rhonchi.
Pulmonary Function Test (PFT) Findings (Moderate to Severe Restrictive Pathophysiology):
- Tidal Volume (): Decreased.
- Inspiratory Reserve Volume (): Decreased.
- Expiratory Reserve Volume (): Decreased.
- Residual Volume (): Decreased.
- Vital Capacity (): Decreased.
- Inspiratory Capacity (): Decreased.
- Functional Residual Capacity (): Decreased.
- Total Lung Capacity (): Decreased.
- ratio: Normal.
- Negative Inspiratory Force () / MIP: Decreased.
Arterial Blood Gases (Moderate to Severe MG/Acute Ventilatory Failure w/ Hypoxemia):
- : Decreased.
- : Increased.
- : Slightly increased.
- : Decreased.
Radiologic Findings on Chest Radiograph:
- Normal in early stages.
- Increased opacity when atelectasis is present.
General Management and Therapeutic Protocols
Monitoring: Frequent measurements of Vital Capacity (), Negative Inspiratory Force (), blood pressure, pulse oxygenation saturation, and arterial blood gases.
Primary Medications:
- Cholinesterase inhibitors (anticholinesterase therapy): Neostigmine (Prostigmin) and Pyridostigmine (Mestinon, Regonol). First attempted usage of these was June 2nd, 1935.
- Immunosuppressants.
- Adrenocorticotropic hormone (ACTH) therapy.
Surgical and Advanced Interventions:
- Thymectomy: Removal of the thymus gland.
- Plasmapheresis.
Respiratory Care Treatment Protocols:
- Oxygen Therapy: Increase up to ; if still hypoxemic, add CPAP/PEEP.
- Hyperinflation Therapy: e.g., IPPB for the treatment of atelectasis.
- Bronchopulmonary Hygiene Protocol: To treat mucus accumulation and airway obstruction.
- Lung Expansion Therapy Protocol.
- Mechanical Ventilation Protocol: Initiated when clinical data demonstrate impending or acute ventilatory failure.
Clinical Indicators for Mechanical Ventilation (Acute Ventilatory Failure):
- .
- .
- or .
Questions & Discussion
Question: The fundamental anatomic alteration found with myasthenia gravis is a problem with:
- Response: B. voluntary muscle acetylcholine () transmission.
Question: All of the following are possible ways that the IgG antibodies found in a myasthenia gravis patient lead to muscle weakness, EXCEPT:
- Answer: D. breakdown the nerves’ myelin sheath (Note: antibodies block , breakdown faster, or destroy receptor sites).
Question: The major pathologic or structural changes of the lungs associated with ventilatory failure accompanying myasthenia gravis include:
- Answer: A. 1 (alveolar consolidation) and 4 (atelectasis).
Question: Commonly encountered chest assessment findings in a patient with myasthenia gravis include:
- Answer: B. 1 (diminished breath sounds) and 3 (crackles and rhonchi).
Question: The most important thing to assess in the myasthenia gravis patient to determine acute ventilatory failure is:
- Options: Peak flow, arterial blood pH, negative inspiratory force, tidal volume measurement.
- Reference data: Negative inspiratory force () and Vital Capacity () are critical monitoring tools.